Avandia Critic Claims FDA Smear Campaign


In the study, Nissen and his co-author report that diabetes patients who took Avandia were 43 percent more likely to have a heart attack than patients who took other medications or a placebo. The drug's manufacturer, GlaxoSmithKline, said it, "strongly disagrees with the conclusions" in Nissen's article, which the company contends "are based on incomplete evidence and a methodology that the author admits has significant limitations."

The FDA responded to the study by issuing a safety alert, recommending that physicians "continue to carefully make individualized treatment decisions" for diabetes patients who take Avandia. At least three congressional committees are planning to investigate Avandia -- and the FDA approval process -- in the coming weeks.

-- This embed didnt make it to copy for story id = 3225419.
  • 1
  • |
  • 2
Join the Discussion
blog comments powered by Disqus
You Might Also Like...